BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21465804)

  • 1. [The role of ADME evaluation in translation research of innovative drug].
    Liu Y; Hong L; Yu LS; Jiang HD; Chen JZ; Meng Q; Chen SQ; Zeng S
    Yao Xue Xue Bao; 2011 Jan; 46(1):19-29. PubMed ID: 21465804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using in vitro human tissues to predict pharmacokinetic properties.
    Huebert ND; Dasgupta M; Chen Y
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):69-74. PubMed ID: 14982150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
    Lin K; Tibbitts J; Shen BQ
    Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
    Srinivas NR
    Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development.
    Ekins S; Williams AJ
    Lab Chip; 2010 Jan; 10(1):13-22. PubMed ID: 20024044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auditing drug metabolism protocols, data, and reports.
    Lucas G; Walls S
    Qual Assur; 1994 Jun; 3(2):193-7. PubMed ID: 7804636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?
    Penner N; Xu L; Prakash C
    Chem Res Toxicol; 2012 Mar; 25(3):513-31. PubMed ID: 22309195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of radioactive compounds and autoradiography to determine drug tissue distribution.
    Solon EG
    Chem Res Toxicol; 2012 Mar; 25(3):543-55. PubMed ID: 22280496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug metabolism and pharmacokinetics in drug discovery.
    Roberts SA
    Curr Opin Drug Discov Devel; 2003 Jan; 6(1):66-80. PubMed ID: 12613278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.
    Nassar AE; Kamel AM; Clarimont C
    Drug Discov Today; 2004 Dec; 9(23):1020-8. PubMed ID: 15574318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the Internet help to meet the challenges in ADME and e-ADME?
    Van de Waterbeemd H; De Groot M
    SAR QSAR Environ Res; 2002; 13(3-4):391-401. PubMed ID: 12184380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward a new age of cellular pharmacokinetics in drug discovery.
    Zhou F; Zhang J; Li P; Niu F; Wu X; Wang G; Roberts MS
    Drug Metab Rev; 2011 Aug; 43(3):335-45. PubMed ID: 21395404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.